Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.
Conference:
Presenting Author:
Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,
Keywords: everolimus, lanreotide, PFS, RCT,
Introduction: Patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) have limited therapeutic options.
Conference:
Presenting Author:
Authors: Capdevila J, Amthauer H, Ansquer C, Deshayes E, Garcia-Carbonero R,
Keywords: radiopharmaceutical therapy, neuroendocrine tumour, [177Lu]Lu-edotreotide, progression-free survival, gastroenteropancreatic,
Introduction: In localised and locally advanced forms neuroendocrine tumours (NETs) of the lung radical surgical resection represents the standard of care, several clinicopathologic factors are potentially associated with recurrence of disease.
Conference:
Presenting Author: Paravani P
Authors: Paravani P, Russo F, Mazzilli R, Zamponi V, Mancini C,
Keywords: radiomics, predictive role, rfs, lung, lung net,
Introduction: Bronchial neuroendocrine neoplasms (NENs) can be subdivided into TCs, ACs and neuroendocrine carcinomas (NECs). Although a few studies have explored treatment approaches and oncological outcomes, most focus on surgical cohorts, small sample sizes, or mixed groups including TC, AC, and NECs. Real-life cohort data are lacking.
Conference:
Presenting Author: Clement D
Authors: Correia J, Sarker D, Dolly S, Frydman A, Srirajaskanthan R,
Keywords: bronchial carcinoid, treatment pattern, recurrence-free survival, overall survival,
Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.
Conference:
Presenting Author:
Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,
Keywords: Merkel cell, skin, radiotherapy,